Market News & Trends
4/3/2012
Aptar Pharma's Device Delivers INSYS Therapeutics' Drug Aptar Pharma recently announced INSYS Therapeutics' SUBSYS, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has…
Allena Pharmaceuticals Licenses Worldwide Rights to Hyperoxaluria Portfolio
Allena Pharmaceuticals, Inc. and Althea Technologies recently announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio,…
Aptar Pharma's Device Delivers INSYS Therapeutics' Drug
Aptar Pharma recently announced INSYS Therapeutics' SUBSYS, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has been launched in the US for breakthrough…
Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Adjuvant
Vical Incorporated recently announced researchers at Ehime University in Japan and their collaborators have developed a Vaxfectin-formulated DNA vaccine candidate with the potential to prevent…
Optimer Pharmaceuticals & Astellas Pharma Strike Deal Worth Up to $110 Million
Optimer Pharmaceuticals, Inc. and Tokyo-based Astellas Pharma Inc. recently announced the execution of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets…
PharmaForm Announces Manufacturing Agreement
PharmaForm recently announced that Corcept Therapeutics Inc. has chosen them as their primary commercial manufacturer for their newly approved drug product, Korlym. The US FDA…
Sunesis Pharmaceuticals & Royalty Pharma Announce $25-Million Royalty Agreement
Sunesis Pharmaceuticals and Royalty Pharma recently announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development…
3/27/2012
Marinomed's Nasal Spray Achieves Positive Clinical Results Marinomed Biotechnologie GmbH, recently announced that data from a clinical trial for the company's iota-carrageenan nasal spray was…
Bend Research Launches New Biotherapeutics Development Initiative
Bend Research Inc. recently announced an initiative to expand its scientific and engineering expertise into biotherapeutics, including offering new technologies and equipment proven to improve…
Bioniche Life Sciences Secures $20 Million
Bioniche Life Sciences Inc. recently announced it has accepted an offer of a $20 million financing from investment funds managed by US-based Capital Royalty L.P.…
FDA Clears Expanded Compatibility for Ikaria's Delivery Systems
Ikaria, Inc., recently announced that the Center for Devices and Radiological Health (CDRH) branch of the US FDA has granted 510(k) clearance for compatibility of…
Marinomed's Nasal Spray Achieves Positive Clinical Results
Marinomed Biotechnologie GmbH, recently announced that data from a clinical trial for the company's iota-carrageenan nasal spray was presented at the 14th International Symposium on…
Nektar Therapeutics Moving 30 Research Jobs
Nektar Therapeutics recently announced it is consolidating its US-based research scientists at the company's existing San Francisco state-of-the-art R&D center, which is located adjacent to…
Particle Sciences & Pernix Therapeutics Enter Development Agreement
Particle Sciences, Inc. recently announced it is developing with Pernix Therapeutics a new topical dermatology product for the pediatric market. "There are multiple treatments for…
Connell Brothers Signs Agreement With World's Top Chemical Company
Connell Brothers Australasia recently announced it was appointed by BASF Australia, a subsidiary of BASF Corporation, the world's leading chemical company, to distribute its human…
DSM & Agennix Sign Commercial Manufacturing Agreement
DSM Pharmaceutical Products and Agennix recently announced they have signed a new contract under which DSM will manufacture the oral Dendritic Cell Mediated Immunotherapy (DCMI)…
Pion Launches Modern, High Throughput Complement to Conventional Franz Cells
Pion Inc. recently introduced the Skin PAMPA Test System, specifically designed to predict the permeability of drugs and dermal formulations through the human skin. The Skin…
ThromboGenics Enters Commercialization Agreement With Alcon
ThromboGenics NV recently announced it has entered into an agreement with Alcon (a division of Novartis), the global leader in eye care, for the commercialization…
Vascular Magnetics to Advance Magnetically Targeted Delivery System
Vascular Magnetics, Inc. recently announced it has raised $7 million in a Series A financing to advance the development of its proprietary, magnetically targeted drug…
3/20/2012
Connell Brothers Signs Agreement With World's Top Chemical Company Connell Brothers Australasia recently announced it was appointed by BASF Australia, a subsidiary of BASF Corporation,…
